Orchestra BioMed Holdings (OBIO) Stock Analysis & AI Equity Report
Orchestra BioMed Holdings (OBIO) overview
Orchestra BioMed Holdings (OBIO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 33.5m and operating profit of USD -51.8m; the year-end share price was 4.15 USD and market capitalisation was USD 237m. Orchestra BioMed Holdings is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Orchestra BioMed Holdings's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Orchestra BioMed Holdings
Orchestra BioMed develops therapeutic technologies through collaborations with medical device companies. Its lead candidates include AVIM Therapy, a bioelectronic therapy designed to lower blood pressure and integrate with cardiac pacemakers, and Virtue Sirolimus AngioInfusion Balloon for artery disease. The company is conducting clinical studies of these candidates and collaborates with Medtronic on AVIM Therapy development for patients with hypertension who are indicated for a pacemaker.
Generate the Orchestra BioMed Holdings report
Orchestra BioMed Holdings is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Orchestra BioMed Holdings and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Orchestra BioMed Holdings
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.